Vaxart

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vaxart reports solid Q1 earnings, progresses in vaccine development

Vaxart's Q1 2024 performance reflects financial stability and progress in vaccine development, particularly with positive Phase I trial results for their norovirus vaccine.
While the company faces challenges in funding, manufacturing, and program prioritization, opportunities lie in advancing COVID-19 vaccine trials and regulatory engagements.
By addressing concerns and leveraging opportunities effectively, Vaxart can strengthen its position in the vaccine market and drive future growth and innovation.

Vaxart reports strong Q3 revenue, advances in COVID and norovirus

Vaxart's Q3 2024 earnings call highlighted revenue from government contracts, progress in COVID, norovirus, and HPV programs, and promising trial data.
The company faces challenges in study enrollment, resource allocation, and regulatory compliance but remains open to collaborations and global vaccine development.
With a cash runway into 2026, Vaxart is well-positioned to leverage market demand for their oral pill vaccine candidates and drive future growth.
Strong performance, constructive FDA feedback, and market opportunities position Vaxart for continued success in vaccine development and partnerships.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in March 2004 and is headquartered in South San Francisco, CA.

Following short-squeeze hopes on Tuesday, Vaxart stock was down Wednesday on news of preliminary Phase I vaccine trial results. The post VXRT Stock: What To Know As Covid-19 Play Vaxart Plummets appeared first on InvestorPlace.

VXRT Stock: What To Know As Covid-19 Play Vaxart Plummets

Vaxart said it observed positive preliminary data from its phase 1 clinical trial of its oral COVID-19 vaccine candidate, but investors weren't buying it. Shares of Vaxart crashed as much as 62% on Wednesday after the company said its VXA-CoV2-1 vaccine candidate did not product antibodies, which indicates little to no immune response to the vaccine among patients.

Vaxart plummets 62% after its oral COVID-19 vaccine fails to produce antibodies (VXRT)

The stock had risen fourfold from late December through Tuesday. It was down 50% on Wednesday.

Lifted by a Short Squeeze, Vaxart Stock Sinks on Lackluster Vaccine News

Vaxart stock crumbled Wednesday after the company said its coronavirus vaccine didn't generate detectable neutralizing antibodies in "most subjects." The post Vaxart Stock Crashes After Oral Covid Vaccine Fails To Produce Antibodies appeared first on Investor's Business Daily.

Vaxart Stock Crashes After Oral Covid Vaccine Fails To Produce Antibodies

Shares of Vaxart Inc. tumbled 42.9% in premarket trading on Wednesday after the company said its oral COVID-19 vaccine candidate was well-tolerated in a Phase 1 clinical trial but it did not generate neutralizing antibodies among participants. Vaxart said its experimental vaccine was immunogenic in the preliminary results; however, it also said that neutralizing antibodies were not detected in serum or IgG antibodies were not found in "most subjects.

Vaxart's stock falls 42% after disclosing preliminary results from early-stage COVID-19 vaccine study

The vaccine, which comes in the form of a small tablet, generated a type of T-cell responsible for destroying virus-infected cells in about 75% of volunteers.

Vaxart says its oral Covid vaccine produced promising results in early trial

SOUTH SAN FRANCISCO, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines administered by tablet, today announced preliminary data from its Phase 1 study of VXA-CoV2-1 showing that its oral COVID-19 tablet vaccine candidate was generally well-tolerated, and immunogenic as measured by multiple markers of immune response to SARS-CoV-2 antigens.

Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

Vaxart (VXRT) stock is heading higher Tuesday and there are a couple of things investors will want to keep in mind about the biotech company. The post VXRT Stock Alert: 2 Things for Vaxart Investors to Know as Shares Pop Today appeared first on InvestorPlace.

VXRT Stock Alert: 2 Things for Vaxart Investors to Know as Shares Pop Today

Gogo

Macy's

The GameStop short-squeeze saga has turned the spotlight on small and mid-cap stocks with a high level of short interest. Heavily shorted stocks could be targeted for so-called social trades by retail investors, who look to set off sharp price increases in these names and put pressure on short.

Vaxart, Macy's, Gogo: Will These Stocks See A GameStop Like Short Squeeze?

Arcturus Therapeutics

Inovio Pharmaceuticals

Probably not, if you're investing for the long term.

Is It Too Late to Buy These 3 COVID Vaccine Latecomer Stocks?

The stock price of Vaxart Inc (NASDAQ: VXRT) is trading at over 25% today. This is why it happened.

VXRT Stock Price Increases Over 25%: Why It Happened

Apple

Amgen

Caterpillar

Dow Inc

Home Depot

Harmony Gold Mining Co Ltd

Johnson & Johnson

Merck

Travelers

Walmart

Two new breakout stocks for Week 5 of 2021 with better than 10% short-term upside potential. This past week all 4 stocks gained over 10% with NBSE and QDEL gaining over 20% before pulling back on Friday to close with average +3.77% gains this week.

Week 5 MDA Breakout Stocks - February 2021: Short-Term Picks To Give You An Edge

A little-known biotech is trying its hand at developing a coronavirus vaccine. Can it succeed?

Is Vaxart Stock a Buy?

After the stock's magnificent run in 2020, it might be time to take profits.

After Its 1,500% Jump, Is It Time to Sell Vaxart Stock?

NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Vaxart, Inc. (NASDAQ: VXRT) concerning the Company and its directors' and officers' possible violations of state laws. If you purchased Vaxart stock, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Tom Kennedy, of GPM, 230 Park Avenue, Suite 530, New York, NY 10169 at tkennedy@g

Glancy Prongay & Murray LLP Announces Investigation of Vaxart, Inc.

Biotech company Vaxart's stock has rallied by about 40% over the last 5 trading days, with a bulk of the gains coming on Monday. The stock is also up by about 76% since the beginning of 2021, compared to the S&P 500 which has gained just about 3% over the same time frame.

Is Vaxart Stock A Buy Ahead Of Phase 1 Data Readout?

SOUTH SAN FRANCISCO, Calif., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, including a Phase 2 ready norovirus program, announced today health care economic findings published in the American Journal of Preventative Medicine. Computational modeling simulating norovirus infection and transmission in a community setting showed that a potential norovirus vaccine can avert symptomatic cases and result in cost savings. The study found, among other things, that vaccination against the norovirus can reduce the economic burden of the virus and is cost effective even if priced at $500 per course when vaccinating children under 5 and older adults, a much higher value than previously estimated. The manuscript titled, “Potential Clinical and Economic Value of Norovirus Vaccination in the Community Setting” can be accessed here .

Vaxart Announces Publication of a Peer-reviewed Journal Article Showing the Potential Clinical and Economic Value of a Norovirus Vaccine

New pre-clinical histology data show that Vaxart's oral vaccine protected against lung inflammation in hamster models

Vaxart Announces Additional Preclinical COVID-19 Oral Vaccine Data and Publication

Biotech company Vaxart stock is up by over 11x through the last 12 months rising to levels of around $7 per share, driven by the company's efforts to develop a Covid-19 vaccine. Vaxart, which focuses on oral recombinant vaccines, is targeting a Covid-19 vaccine that can be administered via tablet.

Is Vaxart Stock Worth The Risk?

Altimmune

No kidding around ... here's how they truly can.

3 Stocks That Could Realistically Triple Your Money in 2021

Beam Global

Blink Charging

Celsius Holdings

Co-Diagnostics

Cardiff Oncology

Genprex

GrowGeneration Corp

Kirkland's

Marathon Digital Holdings

Nautilus

Novavax

Plug Power

Riot Blockchain

AgEagle Aerial Systems

Veritone

Waitr Holdings Inc

This article looks at the 17 companies listed on U.S. exchanges that had a higher total return than high-flying Tesla in 2020. The stocks tended to be microcap to small cap stocks in sectors that piqued investor interest in 2020.

The 17 Stocks That Outperformed Tesla In 2020

These companies' vaccines could bring in billions of dollars in revenue.

Better Coronavirus Stock: Novavax or Vaxart?

A10 Networks

National Vision Hlds

Smith & Wesson Brands

Tronox

Unisys

VirnetX

These are the small cap stocks with the best value, fastest growth, and most momentum for February 2021.

Top Small Cap Stocks for February 2021

There are some warning signs around this vaccine-maker that investors should take seriously.

Why I'm Not Buying Vaxart Stock

2 COVID Vaccine Stocks That Could Trounce Pfizer and Moderna in 2021

News for Vaxart Stock (VXRT)